All articles tagged with #phase 2 trial
Bristol Myers Squibb claims Phase 2 success for a GPRC5D-targeted CAR-T therapy in multiple myeloma, underscoring the potential of this target while noting ongoing questions about durability and outcomes after progression.
Roivant’s $14 million upfront investment and a $294 million Bayer deal for mosliciguat paid off after a Phase 2 PHocus trial in 135 PH‑ILD patients across 20 countries, showing a 56.3% placebo‑adjusted reduction in pulmonary vascular resistance at Week 16, a 35.2‑meter improvement in 6‑minute walk distance, and a 53.2% drop in NT‑proBNP, with lower cough rates (12.1% vs 18.2% placebo). The data support mosliciguat as a potential single‑agent and/ or combination therapy, and Roivant has moved it into Phase 3, aiming to reach about 200,000 PH‑ILD patients in the US and Europe.
In a 48-patient Phase 2 study for the rare blood cancer polycythemia vera, Silence Therapeutics' RNA drug divesiran achieved a clinical response in 88% of treated patients versus 19% on placebo, suggesting robust efficacy and potential competitiveness with Takeda's near-approval therapy.
A phase 2 JAMA trial with 450 vaccinated adults in Germany found that using azelastine nasal spray (3–5 times daily for ~56 days) reduced COVID-19 infection risk to 2.2% vs 6.7% for placebo, shortened illness duration (3.4 vs 5.14 days), and lowered overall viral infections (8.4% vs 18.8%). Side effects were usually mild (e.g., bitter taste, nosebleeds, fatigue). Experts say it could be complementary to vaccines but not a substitute, and more research is needed before recommending it as a preventive measure.
Vertex Pharmaceuticals announced that its experimental pain drug VX-993 failed to outperform placebo in a Phase 2 trial, leading to the discontinuation of its development as a single-agent for acute pain, though the company will continue testing it for chronic nerve pain in diabetic patients.
Viking Therapeutics' stock soared after positive data from its weight-loss drug trial, making the company an attractive takeover target. Analysts raised price targets and reiterated buy ratings, citing the drug's potential to outperform competitors. The company is also developing a treatment for NASH and plans to discuss next steps with the FDA. The stock has gained 392% year-to-date, outperforming the S&P 500.
Viking Therapeutics' stock doubled after reporting positive results from a Phase 2 trial of its weight-loss drug VK2735, showing statistically significant reductions in body weight at all doses compared to placebo, with patients losing up to 14.7% of their body weight after 13 weeks. The treatment was well-tolerated, and the company plans to discuss next steps with the FDA. The news positions Viking as a potential competitor in the weight-loss drug market, and the company is also developing a treatment for NASH.
Novavax's COVID-Influenza Combination, stand-alone influenza, and high-dose COVID vaccine candidates have demonstrated robust immune responses in a Phase 2 trial. The trial evaluated the safety and effectiveness of different formulations of the vaccine candidates in adults aged 50 through 80. All three vaccine candidates contained Novavax's patented Matrix-M adjuvant and showed reassuring preliminary safety profiles and reactogenicity that was comparable to authorized influenza vaccine comparators. The CIC vaccine candidate achieved both immunoglobulin G (IgG) and neutralizing levels comparable to Novavax's prototype COVID vaccine (NVX-CoV2373).